Therapy

Javier P. Gisbert, José María Pajares, I. Rácz

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

During the past year omeprazole-based triple therapies have achieved relatively low eradication rates, which lends support to the assertion that new regimens need to be developed. Other proton pump inhibitors (lansoprazole, pantoprazole, rabeprazole and esomeprazole) and ranitidine bismuth citrate have achieved results that are comparable to those of omeprazole. The optimal duration of eradication treatment (7-14 days) remains controversial. Second-line regimens, for use when eradication treatment with first-line regimens fails, have achieved high cumulative eradication rates. There is still a need for new compounds that are specific for Helicobacter pylori.

Original languageEnglish
JournalCurrent Opinion in Gastroenterology
Volume17
Issue numberSUPPL. 1
Publication statusPublished - 2001

Fingerprint

Omeprazole
Rabeprazole
Esomeprazole
Lansoprazole
Proton Pump Inhibitors
Helicobacter pylori
Therapeutics
pantoprazole
ranitidine bismuth citrate

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Gisbert, J. P., Pajares, J. M., & Rácz, I. (2001). Therapy. Current Opinion in Gastroenterology, 17(SUPPL. 1).

Therapy. / Gisbert, Javier P.; Pajares, José María; Rácz, I.

In: Current Opinion in Gastroenterology, Vol. 17, No. SUPPL. 1, 2001.

Research output: Contribution to journalArticle

Gisbert, JP, Pajares, JM & Rácz, I 2001, 'Therapy', Current Opinion in Gastroenterology, vol. 17, no. SUPPL. 1.
Gisbert JP, Pajares JM, Rácz I. Therapy. Current Opinion in Gastroenterology. 2001;17(SUPPL. 1).
Gisbert, Javier P. ; Pajares, José María ; Rácz, I. / Therapy. In: Current Opinion in Gastroenterology. 2001 ; Vol. 17, No. SUPPL. 1.
@article{f0df7c374049403d92adff1f55135749,
title = "Therapy",
abstract = "During the past year omeprazole-based triple therapies have achieved relatively low eradication rates, which lends support to the assertion that new regimens need to be developed. Other proton pump inhibitors (lansoprazole, pantoprazole, rabeprazole and esomeprazole) and ranitidine bismuth citrate have achieved results that are comparable to those of omeprazole. The optimal duration of eradication treatment (7-14 days) remains controversial. Second-line regimens, for use when eradication treatment with first-line regimens fails, have achieved high cumulative eradication rates. There is still a need for new compounds that are specific for Helicobacter pylori.",
author = "Gisbert, {Javier P.} and Pajares, {Jos{\'e} Mar{\'i}a} and I. R{\'a}cz",
year = "2001",
language = "English",
volume = "17",
journal = "Current Opinion in Gastroenterology",
issn = "0267-1379",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Therapy

AU - Gisbert, Javier P.

AU - Pajares, José María

AU - Rácz, I.

PY - 2001

Y1 - 2001

N2 - During the past year omeprazole-based triple therapies have achieved relatively low eradication rates, which lends support to the assertion that new regimens need to be developed. Other proton pump inhibitors (lansoprazole, pantoprazole, rabeprazole and esomeprazole) and ranitidine bismuth citrate have achieved results that are comparable to those of omeprazole. The optimal duration of eradication treatment (7-14 days) remains controversial. Second-line regimens, for use when eradication treatment with first-line regimens fails, have achieved high cumulative eradication rates. There is still a need for new compounds that are specific for Helicobacter pylori.

AB - During the past year omeprazole-based triple therapies have achieved relatively low eradication rates, which lends support to the assertion that new regimens need to be developed. Other proton pump inhibitors (lansoprazole, pantoprazole, rabeprazole and esomeprazole) and ranitidine bismuth citrate have achieved results that are comparable to those of omeprazole. The optimal duration of eradication treatment (7-14 days) remains controversial. Second-line regimens, for use when eradication treatment with first-line regimens fails, have achieved high cumulative eradication rates. There is still a need for new compounds that are specific for Helicobacter pylori.

UR - http://www.scopus.com/inward/record.url?scp=4243958372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4243958372&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:4243958372

VL - 17

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

SN - 0267-1379

IS - SUPPL. 1

ER -